BC Innovations | Jun 14, 2017
Strategy

Threshold to academia

By C. Simone Fishburn, Editor, BioCentury Innovations In transitioning from industry to academia, former CEO of Threshold Pharmaceuticals Inc. Barry Selick wants to walk a fine line between the two worlds, increasing the returns on...
BC Extra | Oct 9, 2014
Company News

Deal-maker Max Link passes away

Max Link, chairman of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Celsion Corp. (NASDAQ:CLSN) and CytRx Corp. (NASDAQ:CYTR) died on Oct. 5. Alexion said Link, who was 74, died unexpectedly while traveling on business. Link had served on...
BC Week In Review | Apr 15, 2013
Company News

Idec, Protein Design Labs deal

IDPH received a worldwide, non-exclusive license to PDLI's antibody humanization patents to develop a humanized MAb to treat steroid-resistant inflammatory diseases. IDPH will pay a license and signing fee of $1.3 million. PDLI can receive...
BC Week In Review | Apr 15, 2013
Clinical News

Protovir human antibody targeted to cytomegalovirus data

PDLI announced results of Phase II testing in 179 people, with a preliminary analysis showing lower incidence of infection, death, or relapse of disease (the primary end points of the trial). The difference was statistically...
BC Week In Review | Apr 15, 2013
Clinical News

Protein Design Labs, Roche regulatory update

The FDA's Biological Response Modifiers Advisory Committee voted unanimously (12-0) to recommend approval of the partners' Zenapax humanized anti-Tac antibody to prevent acute rejection episodes in kidney transplantation (see Cover Story, BioCentury Part I). Protein...
BioCentury | Dec 24, 2007
Strategy

Big antibody deals

Big antibody deals Partners Year Potential value Description Genmab (CSE:GEN) GlaxoSmithKline (LSE:GSK; GSK) 2006 $2,059 GSK receives global exclusive rights to co-develop and commercialize GEN's ofatumumab for cancer and autoimmune diseases. The biotech receives a...
BC Week In Review | Apr 30, 2007
Company News

Protein Design Labs antibodies news

PDLI said the opposition division of the European Patent Office (EPO) upheld the company's European Patent No. EP 0 451 216 covering antibody humanization. The company said the patent is now "virtually identical" to when...
BC Week In Review | Aug 28, 2006
Company News

Alexza management update

Alexza Pharmaceuticals Inc. (ALXA), Palo Alto, Calif.   Business: Drug delivery   Hired: Michael Taylor as VP of preclinical development, formerly a senior director of preclinical and clinical development sciences at Protein Design Labs Inc....
BC Week In Review | Jan 16, 2006
Company News

Human Genome Sciences, PDL BioPharma deal

HGSI's CoGenesys division granted PDLI an exclusive worldwide license to IP covering an undisclosed antigen. CoGenesys will receive an upfront licensing fee and is eligible for development milestones and royalties. Also, CoGenesys will receive access...
BC Week In Review | Jan 16, 2006
Company News

Protein Design Labs renal, inflammation, autoimmune news

The company changed its name to PDL BioPharma Inc. Protein Design Labs Inc. (PDLI), Fremont, Calif.   Business: Renal, Inflammation, Autoimmune  ...
Items per page:
1 - 10 of 528
BC Innovations | Jun 14, 2017
Strategy

Threshold to academia

By C. Simone Fishburn, Editor, BioCentury Innovations In transitioning from industry to academia, former CEO of Threshold Pharmaceuticals Inc. Barry Selick wants to walk a fine line between the two worlds, increasing the returns on...
BC Extra | Oct 9, 2014
Company News

Deal-maker Max Link passes away

Max Link, chairman of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Celsion Corp. (NASDAQ:CLSN) and CytRx Corp. (NASDAQ:CYTR) died on Oct. 5. Alexion said Link, who was 74, died unexpectedly while traveling on business. Link had served on...
BC Week In Review | Apr 15, 2013
Company News

Idec, Protein Design Labs deal

IDPH received a worldwide, non-exclusive license to PDLI's antibody humanization patents to develop a humanized MAb to treat steroid-resistant inflammatory diseases. IDPH will pay a license and signing fee of $1.3 million. PDLI can receive...
BC Week In Review | Apr 15, 2013
Clinical News

Protovir human antibody targeted to cytomegalovirus data

PDLI announced results of Phase II testing in 179 people, with a preliminary analysis showing lower incidence of infection, death, or relapse of disease (the primary end points of the trial). The difference was statistically...
BC Week In Review | Apr 15, 2013
Clinical News

Protein Design Labs, Roche regulatory update

The FDA's Biological Response Modifiers Advisory Committee voted unanimously (12-0) to recommend approval of the partners' Zenapax humanized anti-Tac antibody to prevent acute rejection episodes in kidney transplantation (see Cover Story, BioCentury Part I). Protein...
BioCentury | Dec 24, 2007
Strategy

Big antibody deals

Big antibody deals Partners Year Potential value Description Genmab (CSE:GEN) GlaxoSmithKline (LSE:GSK; GSK) 2006 $2,059 GSK receives global exclusive rights to co-develop and commercialize GEN's ofatumumab for cancer and autoimmune diseases. The biotech receives a...
BC Week In Review | Apr 30, 2007
Company News

Protein Design Labs antibodies news

PDLI said the opposition division of the European Patent Office (EPO) upheld the company's European Patent No. EP 0 451 216 covering antibody humanization. The company said the patent is now "virtually identical" to when...
BC Week In Review | Aug 28, 2006
Company News

Alexza management update

Alexza Pharmaceuticals Inc. (ALXA), Palo Alto, Calif.   Business: Drug delivery   Hired: Michael Taylor as VP of preclinical development, formerly a senior director of preclinical and clinical development sciences at Protein Design Labs Inc....
BC Week In Review | Jan 16, 2006
Company News

Human Genome Sciences, PDL BioPharma deal

HGSI's CoGenesys division granted PDLI an exclusive worldwide license to IP covering an undisclosed antigen. CoGenesys will receive an upfront licensing fee and is eligible for development milestones and royalties. Also, CoGenesys will receive access...
BC Week In Review | Jan 16, 2006
Company News

Protein Design Labs renal, inflammation, autoimmune news

The company changed its name to PDL BioPharma Inc. Protein Design Labs Inc. (PDLI), Fremont, Calif.   Business: Renal, Inflammation, Autoimmune  ...
Items per page:
1 - 10 of 528